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Abstract
Usher syndrome type 1C (USH1C) occurs in a small population of Acadian descendants from southwestern Louisiana.
Linkage and linkage disequilibrium analyses localize USH1C to chromosome 11p between markers D11S1397 and
D11S1888, an interval of less than 680 kb. Here, we refine the USH1C linkage to a region less than 400 kb, between genetic
markers D11S1397 and D11S1890. Using 17 genetic markers from this interval, we have isolated a contiguous set of
60 bacterial artificial chromosomes (BACs) that span the USH1C critical region. Exon trapping of BAC clones from this
region resulted in the recovery of an exon of the nuclear EF-hand acidic (NEFA) gene. However, DNA sequence analysis of
the NEFA cDNA from lymphocytes of affected individuals provided no evidence of mutation, making structural mutations
in the NEFA protein unlikely as the cellular cause of Acadian Usher syndrome. z 1998 Elsevier Science B.V. All rights
reserved.
The Usher syndromes are a group of clinically and genetically heterogeneous disorders characterized by
sensorineural hearing impairment and retinitis pig-
mentosa [1]. Clinically, three types of Usher syn-
drome have been described. Patients with Type I
disease have severe to profound congenital hearing
impairment, vestibular dysfunction, and retinal de-
generation beginning in childhood, while those with
Type II disease have moderate to severe hearing im-
pairment, normal vestibular function, and later onset
of retinal degeneration [2]. The hearing loss in Type
III disease is progressive and the age of onset of
0925-4439 / 98 / $19.00 ß 1998 Elsevier Science B.V. All rights reserved. All rights reserved.
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PCR, polymerase chain reaction; RT, reverse transcription;
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retinal degeneration is variable [3]. Linkage studies
predict at least nine di¡erent loci for Usher syn-
dromes, and one locus, USH1B, has been identi¢ed
as the gene encoding the unconventional, nonmuscle
myosin type VIIa [4].
Type I Usher syndrome occurs in populations
throughout the world, including a small southwest-
ern Louisiana population descended from French-
speaking emigrants exiled from Acadia (southeastern
maritime Canada) by British occupancy forces in the
mid-eighteenth century [5]. Two of us previously lo-
calized Acadian Usher syndrome (USH1C) to the
p15.1^p14 region of chromosome 11 [1] and showed
by linkage and linkage disequilibrium analyses that it
lies between the genetic markers D11S861 and
D11S899, a distance of approximately 2^3 centiMor-
gans [6]. Ayyagari et al. [7] subsequently re¢ned the
USH1C region to the interval between genetic
markers D11S1397 and D11S1888. All a¡ected indi-
viduals of Acadian ancestry have shown linkage to
the USH1C locus, and no non-Acadian families have
been found that show such linkage, suggesting a
founder e¡ect for Usher syndrome type 1C in the
Acadian population [1,6]. Nouri et al. [8] estimated
that the USH1C mutation was introduced in the
Acadians approximately 15 generations ago.
Bacterial arti¢cial chromosomes (BACs) and P1-
derived arti¢cial chromosomes (PACs) have a num-
ber of properties that make them desirable for
physical mapping. BACs and PACs are capable of
faithful propagation of DNA fragments greater than
300 kb in size [9^12]. The basis for the stability and
non-chimeric nature of the clones is the single copy
number origin of the vectors, method of library
construction, and bacterial host strain [9^12]. The
BAC and PAC libraries are well suited to bridge
the gaps in maps based on yeast arti¢cial chromo-
somes (YACs) using sequence tagged sites (STSs) as
anchors to provide high resolution templates for sub-
sequent large scale DNA sequence analysis [11,12].
In this paper, we re¢ne the candidate interval for
USH1C, present a complete BAC contig of the re-
gion, localize the nuclear EF-hand acidic (NEFA)
gene to the candidate region, and provide evidence
that NEFA is probably not responsible for USH1C.
The families analyzed in this study were previously
described by Keats et al. [6]. The 46 a¡ected individ-
uals have a con¢rmed diagnosis of Usher syndrome
type I and are of Acadian ancestry. The 46 a¡ected
individuals belong to 27 nuclear families from which
a total of 54 disease and 50 normal chromosomes
were available for analysis. Eleven polymorphic mi-
crosatellite markers (D11S1397, D11S902,
D11S4096, D11S4160, D11S921, D11S4099,
D11S1890, D11S4138, D11S4130, D11S1888,
D11S1310) from the Whitehead Institute/Massachu-
setts Institute of Technology Center for Genome Re-
search integrated map [13,14] that are in the vicinity
of the USH1C locus were used to re¢ne the critical
region by haplotype analysis. The 54 disease chromo-
somes had identical haplotypes from D11S902 to
D11S4099. Two chromosomes had a di¡erent allele
at D11S1397 and one chromosome had a di¡erent
allele at D11S1890. The consistency of the haplo-
types argues strongly for a founder e¡ect with this
disease locus, and the loss of disequilibrium at these
genetic loci is consistent with the USH1C locus lying
between D11S1397 and D11S1890, a physical dis-
tance of less than 400 kb on chromosome 11p (Fig.
1).
Individual clones were isolated from a total human
genomic BAC library commercially available from
Research Genetics (Releases I, II and III). This li-
brary contains approximately 221 000 independent
clones (average insert size 130 kb) arranged in a mi-
crotiter format of 72 superpools representing 9-fold
coverage of the human genome. The human BAC
library was screened by polymerase chain reaction
(PCR) ampli¢cation of 21 microsatellite markers
(D11S1397, D11S902, D11S4096, D11S4160,
C
Fig. 1. A BAC contig encompassing the USH1C critical region. The region depicted here from D11S1397 to D11S1888 is covered
contiguously in 60 BAC clones that span an approximate distance of 600 kb. A scale of physical distance is denoted in the top line of
the ¢gure. Genetic markers are spaced along the genetic map in the second line of the ¢gure according to the approximate physical
distance between them. BAC clones are represented by horizontal lines beneath the genetic map of the region. Individual clones are
identi¢ed by plate and well addresses directly beneath and to the left of the line segment and are scaled according to size. Open circles
on a clone denote positive ampli¢cation for the genetic markers denoted by gray rectangles on the genetic map. Vertically hatched
horizontal lines indicate BAC clones subjected to exon trapping.
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D11S1981, D11S1059, D11S921, D11S1228,
D11S4099, D11S1890, D11S4138, D11S4130,
D11S1888, D11S1310, and D11S2450; 18b1(R),
966e8(L), KCNC1, 239h11(L), BIR, and MYOD1)
using primer sets previously described [7,13,14,15]
and commercially available (Research Genetics). All
ampli¢cations were performed on 1 Wg of BAC DNA
in an MJ Research Thermocycler PTC200 for
35 cycles of 94³C for 1 min, 50^60³C (annealing tem-
peratures speci¢c to each primer set) for 1 min, and
72³C for 1 min, with an initial denaturation at 95³C
for 5 min, in 25 Wl reactions each containing 0.132
WM each primer, 0.2 mM dNTPs (Pharmacia);
1.5 mM Mg2 ; 1URediLoad (Research Genetics),
and 2.0 U of Taq polymerase in accompanying bu¡er
(Perkin Elmer). The PCR products were subjected to
electrophoresis on a 2% agarose gel with 0.4 Wg/ml
ethidium bromide to identify clones that contained
each genetic marker. Seventeen microsatellite
markers (D11S1397, D11S902, D11S4096, BIR,
D11S4160, D11S1981, D11S1059, D11S921,
D11S1228, D11S4099, D11S1890, 18b1(R),
966e8(L), D11S4138, D11S4130, KCNC1,
D11S1888) successfully ampli¢ed PCR products.
No clones were obtained using markers D11S1310,
D11S2450, 239h11(L), and MYOD1. A total of 76
BACs were isolated using the 17 STSs, and 60 BACs
were used to construct the contig across the USH1C
candidate region (Fig. 1).
Small preparations of BAC DNA were made from
5 ml cultures grown overnight in 1ULuria^Bertani
medium supplemented with 12.5 Wg/ml chloramphe-
nicol using a modi¢cation of the alkaline lysis mini-
prep procedure [16]. The standard alkaline lysis mini-
prep procedure was modi¢ed in the following way:
200 Wl of solution I, 400 Wl of solution II, and 300 Wl
of solution III was used; 1 volume of isopropanol
was used to precipitate the DNA; and the DNA was
resuspended in 30 Wl of 10 mM Tris-HCl (pH 7.4)
0.1 mM ethylenediaminetetraacetate (EDTA). In or-
der to determine the size of exogenous insert DNA
NotI digests of BAC DNA preparations were per-
formed in 15 Wl reactions containing about 1 Wg of
miniprep DNA, 1Ubovine serum albumin, and 2.5 U
of NotI in accompanying bu¡er (New England Bio-
labs). Digested BACs were fractionated on 1% agar-
ose gels in 0.5UTris-borate-EDTA bu¡er using a
clamped homogeneous electric ¢eld (CHEF) mapper
(Bio-Rad) with 4 kb as the lower setting and 300 kb
as the upper setting on autoalgorithm. BAC insert
sizes were determined by comparison to Midrange
Pulsed Field Gel Marker II and Lowrange Pulsed
Field Gel Marker II (New England Biolabs).
Southern blots of EcoRI digested BAC miniprep
DNA were used to con¢rm overlap between clones
[11,17]. EcoRI digests of BAC DNA were performed
in 40 Wl reactions containing 1.5 Wg DNA and 1 U of
EcoRI in accompanying bu¡er (New England Bio-
labs). Digested BACs were fractionated on 0.8%
agarose/0.5UTris-borate EDTA gels and transferred
to Hybond N membranes (Amersham) by capillary
action [16]. To prepare hybridization probes from
BAC DNAs, 100^200 ng of miniprep DNA was ra-
diolabeled with [K-32P]dCTP by random priming
(Boehringer-Mannheim). Labeled DNA was puri¢ed
using G-50 Sephadex columns. Alternatively, hybrid-
ization probes were also generated by inter-Alu PCR
ampli¢cation of 100 ng of BAC DNA, using the
primers Alu-5P and Alu-3P as described by Tagle
and Collins [18]. Probes were prepared for hybrid-
ization as described above, except that the PCR
products were puri¢ed with Microcon-100 columns
(Amicon) prior to labeling [19]. Puri¢ed, labeled
DNA was preannealed with both 500 Wg/ml of Cot-
1 DNA (Gibco) and 500 Wg/ml of pBeloBAC11 vec-
tor DNA (Research Genetics) by boiling for 5 min
and incubation at 65³C for 2 h prior to hybridization
Fig. 2. Analysis of NEFA gene expression by RT-PCR. Puta-
tive NEFA cDNAs were ampli¢ed from RNA derived from
various cell lines and separated by 1% agarose gel electrophore-
sis in the presence of 0.4 Wg/ml ethidium bromide. Lanes left to
right: putative NEFA cDNAs from GM10354, GM10618, Y79,
HepaG2, SHSY5Y, and PC3 cell lines.
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[19]. Southern blots were prehybridized for 3 h at
65³C in 0.6 M NaCl, 0.02 M EDTA pH 8.0, 0.2 M
Tris-HCl pH 8.0, 2% sodium dodecyl sulfate (SDS),
and 0.1% sodium pyrophosphate, followed by hy-
bridization for 16 h at 65³C in 50 ml of fresh prehy-
bridization solution containing 1U107 cpm/ml pre-
annealed BAC-derived probes [19]. Filters were
washed twice in 2Ustandard saline citrate (SSC),
0.1% SDS at 65³C for 20 min, and once in
0.2USSC, 0.1% SDS at 65³C for 20 min. Filters
were then exposed to X-ray ¢lm (Kodak) for 2^3
days at 380³C.
Assembly of the BAC clones spanning the region
from D11S1397 to D11S1888 encompassing the
USH1C critical region was accomplished by two in-
dependent means: (a) PCR analysis of all 60 BAC
clones for the presence or absence of each of the 17
genetic markers; (b) EcoRI restriction digests and
Southern blots using whole BAC DNA as hybridiza-
tion probes [17] or inter-Alu PCR products from the
BACs as probes [19]. Hybridization experiments us-
ing EcoRI digested BACs con¢rmed overlapping re-
gions suggested by STS analysis.
The region from D11S1397 to D11S1888 is cov-
ered contiguously in 60 BAC clones with an approx-
imate distance of 600 kb (Fig. 1). This interval was
previously reported as less than 680 kb based on the
size of a single YAC (776e7) that spanned a slightly
larger interval ([7]; our unpublished data). Our map
represents a 10-fold average coverage of this region.
Using NotI restriction digests of individual BAC
clones the average size of the clones within the contig
is approximately 105 kb. The depth of clone cover-
age varies from two clones at D11S1397 to 30 inde-
pendent clones at D11S4160. The 60 BACs form a
contig with complete coverage of the D11S1397^
D11S1888 USH1C candidate region.
We compared our map with other existing maps of
the region. The physical distance of our map con-
taining D11S902, D11S4096, D11S4160, D11S921,
D11S4099, D11S4138, D11S4130 and D11S1888 is
550 kb while the physical distance of this region in
the Whitehead Institute/Massachusetts Institute of
Technology Center for Genome Research map of
human chromosome 11 is slightly larger than 400
kb [20]. However, the physical distance of the White-
head Institute/Massachusetts Institute of Technology
Center for Genome Research map may be an under-
estimate since it is only inferred from the genetic
map. The STS order of our map (D11S1397^
D11S902^BIR^D11S921^D11S1890^966e8(L)^
KCNC1^D11S1888) is in agreement with a previ-
ously published YAC contig of this region [7]. The
order of D11S902^D11S1981^D11S1059^D11S921^
D11S1228^D11S1890 is also in agreement with the
McDermott Center for Human Growth and Devel-
opment chromosome 11 map [15]. A single di¡erence
in marker assignment between our map and the
YAC based map of Ayyagari et al. [7] involves the
placement of marker 18b1(R). We placed genetic
marker 18bI(R) closer to the centromere. However,
the YAC used to localize 18bI(R) in the previous
map is chimeric for two di¡erent chromosomes,
and this may be the cause of the discrepancy [7].
The order of genetic markers in this region shows
some correspondence with a recently reported YAC
and PAC contig with the following marker order
D11S1890^D11S921^D11S902^MYOD1^D11S1888^
D11S1310^TPH^SAA1^LDHA [21]. The di¡erence
between the previously reported genetic and physical
map of this region and our map may have also re-
sulted from the use of chimeric YACs [21]. There-
fore, the contig is concordant with most of the other
genetic and physical maps of this area [7,15,20].
Exon trapping was performed using a modi¢ed
pSLP IV vector, kindly provided by Ken Able (Uni-
versity of Michigan), on nine BACs in the USH1C
candidate region (320D19, 232B22, 491D2, 108D23,
41B1, 51K11, 66I10, 41B2, 41C1) (Fig. 1). BAC
DNA was digested with either PstI or both BamHI
and BglII and ligated to pSLP IV. Pooled pSLP
BAC subclone DNA preparations were transfected
into COS-7 cells using LipofectACE (Gibco). RNA
from transfected COS-7 cultures was puri¢ed and
subjected to both reverse transcription and two
rounds of PCR ampli¢cation as previously described
to identify putative exons [22]. Ampli¢cation prod-
ucts were cloned into pAMP10 using the uracil DNA
glycosylase cloning system (Gibco). Colonies of
pAMP-exon clones were selected (192 colonies for
each BAC subcloned) and arrayed into 96-well plates
for size determination by PCR ampli¢cation (1.25 U
of Taq polymerase, 1.25 mM Mg2, 0.25 mM
dNTPs), using forward primer 5P-ACGCTCTA-
GAGTCGACCCAGC-3P and reverse primer 5P-
CCCCTCGGGAGATCTCCAG-3P (for 30 cycles of
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94, 60, and 72³C for 1 min each on a Perkin^Elmer
9600 thermocycler). A human immunode¢ciency vi-
rus (HIV) probe was used to screen clones that uti-
lized the pSPL IV cryptic splice site. Sequence sim-
ilarity analysis of putative exons was performed
using the National Center for Biotechnology Infor-
mation basic local alignment search tool (BLAST)
algorithm [23].
Putative trapped exons from three BACs (41B1,
41B2 and 41C1) were subjected to DNA sequencing.
About 20% of all pSPL-BAC subclones were deter-
mined to be either artifact or clones that utilized the
cryptic splice site during their expression in COS
cells. The sizes of individual trapped exons were de-
termined following PCR ampli¢cation and varied
from approximately 108 bp (vector only) to 300 bp.
Subclones which ampli¢ed putative exons larger than
108 bp that did not hybridize with the HIV artifact
probe were hybridized to restriction digests of the
three D11S921-positive BAC clones to con¢rm their
origin. A BLAST sequence comparison of the ¢ve
con¢rmed exons revealed that only one showed a
high degree of identity to a known gene, the human
NEFA gene (about 100 bp of a trapped exon showed
100% sequence identity to a region delimited by nu-
cleotides 487 (+267) through 586 (+366) of the pre-
viously reported NEFA coding sequence) [24]. Other
exons trapped by this procedure are presently under-
going detailed analyses.
To assess the possibility that expression of NEFA
is involved in the progression of a disease that causes
retinitis pigmentosa, reverse transcription-PCR (RT-
PCR) was performed on RNA from Y79 retinoblas-
toma, as well as HepaG2 hepatocarcinoma, SHSY5Y
neuroblastoma, and PC3 prostate cancer cells. RNA
was prepared by the guanidinium isothiocyanate-
phenol-chloroform extraction method [25]. cDNA
was synthesized using the Reverse Transcription Sys-
tem (Promega) and a speci¢c oligonucleotide primer,
NEFA 3.1 (5P-AAGTTCTGGTGGACTTCAGA-
CT-3P), derived from the 3P-untranslated region
of the NEFA cDNA sequence. Putative NEFA
cDNAs were ampli¢ed by PCR using the primers
NEFA 5.1 (5P-AAAATTATTTACCTGCCTGAAC-
3P) from the 5P-untranslated region of the NEFA
cDNA and NEFA 3.1 (0.6 WM each) under the fol-
lowing conditions: 3 U of Promega Taq polymerase
in accompanying bu¡er, together with 3.0 mM Mg2
and 0.25 mM dNTPs, in a 35-cycle reaction of 95³C
for 20 s, 46.3³C for 20 s, and 72³C for 1 min, with an
initial denaturation of 95³C for 2 min and a terminal
extension of 72³C for 6 min. Expression and relative
sizes of the NEFA cDNA were determined by agar-
ose gel electrophoresis in the presence of 0.4 Wg/ml
ethidium bromide. Fig. 2 shows ampli¢cation of pu-
tative NEFA cDNAs that correspond to the 1262-bp
size predicted by ampli¢cation with primers NEFA
5.1 and NEFA 3.1. Expression of the NEFA cDNA
was restricted to a few cell types, including Y79 ret-
inoblastoma.
The NEFA cDNA was also ampli¢ed from two
lymphoblastoid cell lines derived from peripheral
lymphocytes of patients with Acadian Usher syn-
drome (lines GM10618 and GM10354 of the Nation-
al Institute of General Medical Sciences Human Ge-
netic Mutant Cell Repository). cDNAs were
synthesized as described above. To facilitate cloning,
the NEFA cDNA was ampli¢ed with both primer
pairs NEFA 5.1a (5P-GTTTAAAATTAATTTA-
CCTTGCCTGAAC-3P) and NEFA 3.6a (5P-GTT-
TACTTTAGGGTGATTTTCATCGT-3P) (as above
with annealing at 45.7³C) and NEFA 5.6a (5P-
GTTTAGAGAATATTTAAAAACATTGA-3P) and
3.1a (5P-GTTTAAGTTCTGGTGGACTTCAGAC-
T-3P) (as above with annealing at 43.9³C), which
generated overlapping products corresponding to 5P
and 3P halves of the complete predicted NEFA cod-
ing region. These primers contained arbitrary 5P-ends
previously described to enhance the addition of non-
template, mono-adenosine overhangs by Taq polym-
erase [26] and thereby facilitate TA-cloning. Am-
pli¢ed NEFA halves were cloned by the TA-Cloning
System (Invitrogen). Independent clones were se-
quenced by the Thermosequenase method (Amer-
sham).
We also performed comprehensive sequence anal-
ysis on cloned RT-PCR material to [1] con¢rm the
identity of RT-PCR products as NEFA, [2] con¢rm
the published sequence of NEFA cDNA, and [3]
determine the nucleotide sequence of NEFA coding
sequence from a¡ected individuals. Full-length cod-
ing sequences of putative NEFA cDNAs from each
a¡ected lymphoblastoid cell source (GM10618 and
GM10354) and a single full-length sequence from
Y79 cell line cDNA were obtained (GenBank acces-
sion numbers AF052642, AF052643 and AF052644,
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respectively). Nucleotide analysis con¢rmed the iden-
tity of RT-PCR products as the NEFA cDNA. In
comparing the three full-length sequences generated
with the published NEFA cDNA sequence, no evi-
dence for mutations in NEFA cDNAs from either
a¡ected patient was observed.
Linkage of the Acadian Usher Syndrome Type I
locus to genetic markers in the p15.2^p14 region of
chromosome 11 was the ¢rst step toward physical
and ¢ne gene mapping of USH1C. Haplotype anal-
ysis demonstrates that USH1C resides between
D11S1397 and D11S1890. In an e¡ort to identify
the USH1C locus, we have assembled a contiguous
and overlapping set of genomic clones derived from
the candidate region on chromosome 11p. The
USH1C BAC contig we report spans a 600-kb inter-
val between D11S1397 and D11S1888 with 60 BACs.
This contig exhibits an average 10-fold coverage, but
some regions, such as the D11S1397 locus, have 2-
fold coverage while the D11S4160 locus has 30-fold
coverage. This di¡erence in coverage of the library
may result from cloning bias inherent in the con-
struction of the BAC library, or di¡erent e¤ciencies
of STS based PCR ampli¢cation. The physical map
of chromosome 11p reported here is a high resolu-
tion BAC-based template for subsequent large-scale
DNA sequence analysis and gene discovery. Since
the map is based upon stable, non-chimeric, se-
quence-ready BAC clones, it is an improvement
over the previously published YAC contig from the
region [7].
Localization of the human NEFA gene to the Aca-
dian Usher syndrome critical region between
D11S4160 and D11S921 supports its analysis as a
candidate gene. The human NEFA gene encodes a
420-amino acid protein [24] that belongs to the nu-
cleobindin family [27]. The NEFA gene was origi-
nally isolated from a lambda-gt11 cDNA expression
library derived from the acute lymphoblastic leuke-
mia cell line KM3 [24]. Although its function is cur-
rently unknown, analysis of the NEFA amino acid
sequence suggests that it acts as a dimeric, Ca2- and
DNA-binding protein. A gene such as NEFA that
encodes a DNA-binding protein is a provocative can-
didate for a genetically heterogeneous disease such as
Usher syndrome. It immediately suggests genomic
control of the expression of multiple loci, whose ex-
pression in turn may be causative or contributory to
the multiple forms of the disease. However, our anal-
ysis of NEFA cDNAs suggest that the defect causing
Acadian Usher syndrome is unlikely to be located
within the coding sequence of NEFA. Therefore,
we conclude that, aside from the possibility of a
change in the expression pattern of the NEFA gene
in a¡ected tissues that has not been detected, the
NEFA gene does not appear to be responsible for
Acadian Usher syndrome.
The BAC contig of the USH1C region of chromo-
some 11p will be a valuable resource to search for
additional candidate genes using exon trapping,
cDNA library screening, and large scale DNA se-
quence analysis. The precise localization of this dis-
ease gene will eventually provide important informa-
tion for use in genetic counseling, as well as major
advances in our understanding of hearing and vision.
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